Leerink Partnrs Raises Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings estimates for shares of Kura Oncology in a report issued on Thursday, November 21st. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($2.19) for the year, up from their prior forecast of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

Several other analysts also recently commented on KURA. UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright increased their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Price Performance

Kura Oncology stock opened at $10.96 on Monday. The stock has a market cap of $852.25 million, a price-to-earnings ratio of -4.64 and a beta of 0.86. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $9.06 and a 12-month high of $24.17. The business’s 50-day simple moving average is $17.88 and its 200 day simple moving average is $19.67.

Institutional Trading of Kura Oncology

Several hedge funds have recently bought and sold shares of KURA. nVerses Capital LLC acquired a new position in Kura Oncology during the 3rd quarter valued at about $25,000. Aaron Wealth Advisors LLC grew its holdings in shares of Kura Oncology by 2.4% in the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after acquiring an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares during the last quarter. Hsbc Holdings PLC boosted its position in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Kura Oncology by 17.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.